
ABSTRACT OF THE DISCLOSURE

A method and composition for treating autoimmune hepatitis in a patient utilizes an immunomodulatory amount of $T\alpha_1$ and an anti-inflammatory amount of a corticosteroid.Acute toxicity studies of $T\alpha_1$ in mice, rats, marmosets and dogs demonstrated no adverse effects at doses up to 0.25 mg/kg/day for 14 days. Chronic toxicity studies of $T\alpha_1$ in mice and marmosets demonstrated no adverse effects at doses up to 1 mg/kg/day for 26 weeks.

This Sheet Has Been Replaced



THIS SHEET HAS BEEN REPLACED